The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer.

ABSTRACT: With the heterogeneous use and interpretation of next-generation molecular imaging and approval of new treatment strategies, therapeutic decision-making for de novo metastatic hormone-sensitive prostate cancer (mHSPC) is becoming increasingly challenging. It is conceivable that patients are treated differently in another country, hospital or by another clinician. Here, we aim to provide insights into the clinical practices, challenges, and unmet needs in the management of de novo mHSPC.In this explorative mixed-method study, a survey was sent to urologists and oncologists in 13 Dutch hospitals from the TripleAiM1 network. Additionally, four patient cases were discussed in multi-disciplinary team consultations in four of these hospitals. Results from the survey and patient cases were then d

SUBMITTER: van Elst T 

PROVIDER: S-EPMC11992181 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature